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The question of Highly Active Antiretroviral Treatment
(HAART) simplification is important due to long term
toxicity and cost of HAART.
Pro-viral HIV DNA associated with Peripheral Blood
Mononuclear Cells (PBMC) is a marker of the HIV
reservoir which is predictive of the evolution of HIV
infection. It remains the only virological quantitative
marker detectable during suppressive HAART. A pro-
viral DNA > 2.7log before treatment interruption is pre-
dictive of a decline of CD4 T lymphocytes after inter-
ruption [1].
We measured PBMC’s pro-viral DNA in patients trea-
ted with triple nucleoside analogue therapy containing
zidovudine who had developed severe lipodystrophy and/
or metabolic abnormalities. A switch to a nucleoside ana-
logue bitherapy by stopping zidovudine was proposed for
patients whose pro-viral DNA was < 2.7 log. We selected
11 patients (mean age 48 years, 5 women, mean duration
of infection=10 years, mean CD4 nadir=288/mm
3, mean
plasma HIV RNA zenith =4,44 log). Patients were on tri-
ple nucleoside analogue therapy for 7 years with plasma
HIV RNA< 40 copies/ml ; mean CD4 cells = 600/mm
3.
Mean pro-viral DNA was 2,43 log copies/million PBMC.
Treatment was switched to abacavir+lamivudine in 5
patients and emtricitabine+tenofovir in 6.
After switch, with a mean follow up of 40 months,
plasma HIV RNA remained< 40 copies/ml without blip
and CD4 cells remained stable.
In conclusion, treatment simplification with an analo-
gue nucleoside bitherapy is possible in a selected group
of patients who were treated with a triple nucleoside
analogue therapy in virological success and had a
PBMC’s associated pro-viral DNA < 2.7 log before treat-
ment simplification.
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